Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | AGTR1 | P30556 | 7/20 | 0.35 |
| ▸ | AGTR2 | P50052 | 7/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9708103 | 0.91 | ADORA2B (0.40) | ADORA2BADORA3AGTR1AGTR2ADORA1 | |
| SCHEMBL9707641 | 0.91 | AGTR1 (0.42) | ADORA2BADORA3AGTR1AGTR2 | |
| SCHEMBL9708641 | 0.90 | ADORA2B (0.42) | ADORA2BADORA3AGTR1AGTR2ADORA1 | |
| SCHEMBL9707522 | 0.90 | AGTR1 (0.44) | AGTR1AGTR2 | |
| SCHEMBL9707499 | 0.89 | MEN1 (0.39) | ADORA2BAGTR1AGTR2ADORA1 | |
| SCHEMBL9707302 | 0.89 | GPR18 (0.38) | PPARGAGTR1AGTR2 | |
| SCHEMBL9707405 | 0.88 | AGTR1 (0.47) | PPARGAGTR1AGTR2 | |
| SCHEMBL9708252 | 0.88 | ADORA3 (0.42) | ADORA2BADORA3PPARGAGTR1AGTR2 | |
| SCHEMBL9707673 | 0.88 | KDM4E (0.37) | ADORA2BPPARGAGTR1AGTR2ADORA1 | |
| SCHEMBL9708367 | 0.88 | AGTR1 (0.45) | PPARGAGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1992007852-A1 | BIPHENYLALKYL XANTHINE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1992-05-14 | — | — | WO | disclosed |